Kazandjian Dickran, Landgren Ola
Myeloma program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health and the Office of Hematology and Oncology Products, Food and Drug Administration, Bethesda, MD.
Myeloma Service, Memorial Sloan-Kettering Cancer Center, New York, NY.
Semin Oncol. 2016 Dec;43(6):682-689. doi: 10.1053/j.seminoncol.2016.10.008. Epub 2016 Nov 16.
The past decade has seen significant advances in our understanding and treatment of multiple myeloma (MM) and its precursor diseases. These advances include gains in knowledge of the underlying pathobiology including molecular and cellular prognostic factors for disease progression. In parallel we have witnessed the availability of novel therapeutics. Together these advances have translated into improvements in long-term clinical benefit and survival in MM. Indeed, it has been shown that patients diagnosed in the last decade have experienced almost doubling of median survival time. We aim to review and give further insight into drug development and novel drug approvals that have revolutionized the treatment of MM.
在过去十年中，我们对多发性骨髓瘤（MM）及其前驱疾病的理解和治疗取得了重大进展。这些进展包括对潜在病理生物学的认识有所增加，包括疾病进展的分子和细胞预后因素。与此同时，我们见证了新型疗法的出现。这些进展共同转化为MM长期临床获益和生存率的提高。事实上，已经表明，在过去十年中诊断出的患者中位生存时间几乎翻了一番。我们旨在回顾并进一步深入了解彻底改变MM治疗的药物研发和新型药物批准情况。
